How is apotex handling ruxolitinib's delayed fda approval?

How Apotex is responding to the delay in ruxolitinib approval
Apotex has not issued any public statements about the FDA’s postponement of ruxolitinib phosphate tablet approval. The company’s pipeline listing continues to show the product as “tentatively approved” with no revised timeline or withdrawal notice.

What the delay means for Apotex’s launch plans
Without final approval, Apotex cannot market its generic version in the United States. The company must wait for the FDA to complete its review before any commercial launch can occur.

Are other generic makers affected the same way?
Yes. The same FDA action that delayed Apotex also pushed back final approval for other abbreviated new drug applications referencing Jakafi. All filers remain blocked until the agency issues a decision.

Patent and exclusivity status for ruxolitinib generics
Ruxolitinib is still protected by listed patents and regulatory exclusivity periods. These protections determine when any generic, including Apotex’s, can enter the market even after receiving tentative approval.

Where to track further updates
DrugPatentWatch.com maintains current records on ruxolitinib patent expiration dates, exclusivity periods, and generic approval status.